Whalesbook
📉 The Financial Deep Dive
Godrej Agrovet Limited (GAVL) has reported a strong performance for its third quarter of Fiscal Year 2026, with consolidated revenues climbing 11% year-on-year to an unspecified but significant figure for the quarter. For the nine months ended December 31, 2025, consolidated revenues grew 9% year-on-year, reaching ₹7,900 crores. Profit Before Tax (PBT), excluding exceptional items, demonstrated robust growth, increasing by 23% year-on-year in Q3 and 17% year-on-year for the nine-month period, standing at ₹482 crores.
Segment Performance Highlights:
- Animal Feed: The business continued its strong volume-led growth, with volumes up 12% year-on-year in Q3. This was largely driven by a substantial 21% increase in cattle feed volumes. Management noted an improvement in EBIT per metric ton.
- Vegetable Oil: This segment delivered a stellar performance with revenue up 27% year-on-year, attributed to improved Fresh Fruit Bunch (FFB) arrivals and a better Oil Extraction Ratio (OER).
- Crop Protection: The business grew revenue by a significant 37% year-on-year, with a focus on generics and specialty products. However, segment results remained flat due to unseasonal rains impacting volumes. Management has set target margins of 28-30% for this segment.
- Astec Life Sciences: This division marked a strong turnaround, with revenues up 33% year-on-year. EBITDA turned positive at ₹5 crores. The company is targeting revenue growth of approximately 20% for FY26 and 15% for FY27, aiming for EBITDA breakeven in FY26.
- Creamline Dairy: Experienced a 3% revenue growth, but its EBITDA declined to ₹11 crores and margins softened to 3%, a consequence of higher milk procurement costs.
- Godrej Foods: Reported stable revenues of ₹215 crores, with EBITDA growing 51% year-on-year to ₹17 crores and margins expanding to 8%, driven by an improved branded contribution.
The Quality:
Margin expansion was evident in the Foods business, reaching 8% due to a stronger branded contribution. Conversely, Creamline Dairy faced margin compression to 3% due to higher milk procurement costs. The Vegetable Oil segment benefited from improved operational efficiencies, while adverse weather conditions impacted the Crop Protection business's profitability.
The Grill:
Management expressed confidence in navigating milk procurement challenges for the dairy business and noted easing price pressures in Astec's enterprise segment. A significant strategic development is the deep strategic review of GAVL's business portfolio, with decisions on value unlocking and capital allocation expected by early April. Looking forward, the Vegetable Oil business is poised for growth via acreage expansion and new processing plants. The Crop Protection segment anticipates healthy growth supported by new product launches, and the Foods business is strategically shifting towards value-added branded retail. The pet food plant is also ready for commissioning.
🚩 Risks & Outlook
- Specific Risks: Key risks include the continued impact of unseasonal rains on Crop Protection volumes and the persistent challenge of higher milk procurement costs affecting Creamline Dairy's profitability. The successful execution of new plant commissions and the strategic outcomes of the portfolio review are also critical.
- The Forward View: Investors will be keenly watching the outcomes of the portfolio review by early April, which could redefine GAVL's strategic direction and capital allocation. The ability of Astec Life Sciences to sustain its turnaround and achieve growth targets, alongside margin recovery in the Dairy segment, will be crucial watchpoints for the coming quarters.